Document:

Exhibit 10.33

 

STRATEGIC ADVISORY AGREEMENT

 

This strategic advisory agreement (“Agreement”)
having an effective date of December 16, 2019, is entered into by and between Zomedica Pharmaceuticals Corp., having its principal
place of business at 100 Phoenix Drive, Suite 190, Ann Arbor, MI 48108 (“Client”) and Johnny D. Powers, an individual
having a principal place of business at 27437 N. 97th Place, Scottsdale, AZ 85262 (“Consultant”).

 

Recitals

 

WHEREAS, Consultant has experience in the fields of medical and diagnostics
industry, specifically veterinary healthcare; and

 

WHEREAS, Consultant is willing to be engaged by Client upon the terms and
conditions herein contained; and

 

WHEREAS, a significant portion of Client’s business and assets are
comprised of Proprietary and Confidential Information, as defined below, which Client wishes to preserve and protect;

 

NOW, THEREFORE, in consideration of the recitals, and of the terms, covenants,
and conditions set forth herein, and for other good and valuable consideration, receipt of which is hereby acknowledged, Client
and Consultant mutually agree as follows:

 

1.   Consulting Services. Client hereby
retains Consultant to render the following services to Client:

 

		·	Work with Client Senior Management to formulate company strategy;

		·	Work with Client Senior Management to establish company goals that drive the strategy

		·	Work with Client Senior Management to implement and evaluate the progress of the goals; and

		·	Such other services as Client may require during the term of this Agreement.

 

Consultant agrees to provide up to 32 hours of such services during any
calendar month of the Agreement term. The timing, manner and means by which Consultant chooses to complete the services are in
Consultant’s sole discretion and control. Consultant’s obligations shall be conditioned upon receiving such information
and cooperation from Client as may be reasonably necessary to perform the services.

 

2.   Services NOT Performed by Consultant.
Although Consultant may comment upon Client’s legal documents, financial statements or other documentation in the course
of performing the services hereunder, Client acknowledges that Consultant is not an attorney, nor is Consultant providing auditing
or accounting services or opining on representations made in any financial statements. Client further acknowledges that Client
should consult with its own legal, auditing and accounting advisors regarding any matters requiring legal, auditing or accounting
advice.

 

     

    

    

 

3.   Relationship of Parties. This
Agreement shall not constitute an employer-employee relationship, and it is the intent of each party that Consultant shall at all
times be an independent contractor.

 

4.   Term. The term of this Agreement
shall commence on the date hereof and shall expire on April 30, 2020 (“Initial Term”). Upon expiration of the Initial
Term, this Agreement shall automatically be renewed month to month thereafter.

 

		5.	Compensation. For services provided hereunder, Consultant shall be paid:
	 	 	 

		a)	The sum of $190 per hour, billable in increments of one-quarter of an hour.

		b)	Following the execution of this Agreement, the Consultant shall be granted 250,000 options to
acquire common shares in the capital of the Client, with an exercise price at fair market value, a two year term and full vesting
on date of grant, subject to establishment and approval by the Board of Directors of the Client in accordance with the Client's
stock option plan.

		c)	Consultant shall only be entitled to payment or reimbursement for travel expenses, food, lodging,
any per diem allowance, equipment, supplies, or similar items if expressly authorized in advance by Client.

 

Consultant will invoice for services provided monthly. Invoices will
be due within 45 days of delivery of each invoice and may be paid via ACH or wire transfer.

 

6.   Ownership. All work product (regardless
of form or media) that Consultant creates in connection with providing the services and/or otherwise delivers to Client shall be
considered to be "works made for hire" under the U.S. Copyright Act, 17 U.S.C. §§ 101 et seq. In the event
such work product is not construed to be a work made for hire, Consultant agrees that Client owns all deliverables that Client
actually pays for, and Consultant hereby assigns all of its rights, title and interests in and to such work product along with
any and all associated intellectual property rights. Consultant further agrees to execute any documents and take any actions reasonably
required by Client to confirm Client's legal title in and to such work product, and any intellectual or other property rights therein.

 

7.   Work Product. Notwithstanding
Section 6, Client acknowledges that Consultant may develop for himself, or for others, problem solving approaches, templates, frameworks,
models, or other tools or information similar to the materials and processes developed in performing the services hereunder, and
nothing contained herein precludes Consultant from developing or disclosing such materials and information, provided that the same
do not contain or reflect Confidential Information.

 

8.   Disclosure of Information. Consultant
agrees that at no time (either during or subsequent to the term of this Agreement) will Consultant disclose or use, except in
pursuit of the business of Client or any of its subsidiaries or affiliates, any Proprietary and Confidential Information of
Client, or any subsidiary or affiliate of Client, acquired during the term of this Agreement. The term “Proprietary and
Confidential Information” shall mean, but is not limited to, all information which is known or intended to be known
only to Client, its subsidiaries and affiliates, and their employees, including any document, record, financial or other
information of Client, or others in a confidential relationship with Client, and further relates to specific business matters
such as the Client’s financial information, identity of clients and patients, policies and procedures, fee structures,
trade secrets, proprietary know-how, account information, and other information relating to other business of Client, its
subsidiaries and affiliates, and their employees. Consultant agrees not to remove from the premises of Client except as
necessary for Consultant to perform services in accordance with the terms of this Agreement, any document, record, or other
information of Client or its affiliates.

 

     

    

    

 

Consultant agrees to return or destroy, immediately upon termination of
Consultant’s services hereunder, any and all documentation relating to Proprietary and Confidential Information of Client
and of others that is in the possession of Consultant, in whatever format it may be maintained, whether provided to, or developed
by, Consultant, and to provide a certificate of destruction if required by Client.

 

Notwithstanding the foregoing, the restrictions contained in this Section
8 shall not apply to any Proprietary and Confidential Information that (i) is a matter of public knowledge or prior personal knowledge
(from a source other than a party to this Agreement or its affiliate), (ii) is independently developed by a person not a party
to this Agreement without the use, directly or indirectly, of Proprietary and Confidential Information, or (iii) is required by
law or the order of any court or governmental agency, or in any litigation or similar proceeding to be disclosed; provided that
the disclosing party shall, prior to making any such required disclosure, notify the other party with sufficient notice to permit
that party to seek an appropriate protective order.

 

9.   Proprietary and Confidential Information
of Others. Consultant acknowledges that Client does business with clients that supply Client with information of a confidential
nature, and that Client has contractual obligations to preserve the confidential nature of such information. Consultant agrees
to treat any information received from clients of Client as confidential, as if it were the Proprietary and Confidential Information
of Client.

 

10.   Remedies. In addition to any
other remedies, which Client may have by virtue of this Agreement, Consultant agrees that in the event that a breach of the confidentiality
provisions of this Agreement occurs or is threatened, Client shall be entitled to obtain an injunction against Consultant from
a court of competent jurisdiction to restrain any breach of confidentiality.

 

11.   Termination. Either party may
terminate this Agreement, with or without cause, upon fifteen (15) days’ advance written notice to the other, unless otherwise
mutually agreed upon.

 

12.   Limitation of Liability to Client.
Notwithstanding any other provision of this Agreement, in no event shall Consultant be liable to Client for Client’s
lost profits, or special, incidental, punitive or consequential damages (even if Consultant has been advised of the possibility
of such damages). Furthermore, in no event shall Consultant’s liability to Client under any circumstances exceed the amount
of compensation actually received by Consultant from Client under this Agreement as of a date certain. Further,

Consultant will not be liable for delays or performance failures due to
circumstances beyond Consultant’s control.

 

     

    

    

 

13.   Indemnification of Consultant. Client
shall indemnify, defend and hold Consultant harmless from and against any and all third party claims, liability, suits, losses,
damages and judgments, joint or several, and shall pay all costs and expenses (including counsel's fees and expenses) as they are
incurred in connection with the investigation of, preparation for or defense of any pending or threatened claim or any action or
proceeding arising there from, that Consultant incurs as a result of having performed services on behalf of Client.

 

14.   Client’s Representations. Client
represents that it has the full right and authority to enter into and perform this Agreement. The consummation of the Agreement
and the transactions contemplated herein do not violate any outstanding assignments, grants, licenses, encumbrances, obligations,
agreements or understanding between Client and any other person or entity. Client represents and warrants to Consultant that Client
is able to timely pay Consultant all fees and expenses incurred in the performance of the services hereunder.

 

15.   Amendments. This Agreement may
be amended only in a written agreement signed by both parties.

 

16.   Independent Consultant; No Agency.
The parties agree that at all times during the term of this Agreement, Consultant shall continue to be an independent Consultant,
and is not authorized as, nor shall be deemed to be an employee, agent, partner, joint venturer, or representative of Client. Neither
party has the authority to bind the other or to incur any liability on behalf of the other, nor to direct the employees of the
other. Nothing in this Agreement shall be interpreted or construed as creating or establishing the relationship of employer and
employee between Client and Consultant or any employee or agent of Consultant. Consultant shall retain the right to perform services
for others during the term of this Agreement.

 

17.   Miscellaneous. No waiver by Client
of any breach of this Agreement by Consultant shall be considered to be a waiver of any other breach. Should any litigation be
commenced between Client and Consultant relating to any such breach, the prevailing party shall be entitled, in addition to such
other relief as may be granted, reasonable costs and attorney’s fees relating to such litigation. If any term or provision
of this Agreement is determined to be illegal or invalid, such illegality or invalidity shall not affect the validity of the remainder
of this Agreement. This Agreement shall be governed by and construed in accordance with the laws of the State of Michigan, without
regard to the jurisdiction in which any action or special proceeding may be instituted.

 

18.   Survival. Sections 4-9, 11-13, 15
and 18 shall survive the expiration or termination of this Agreement.

 

19.   Counterparts. This Agreement may
be executed by the parties in two (2) or more counterparts, each of which will be an original and all of which will be one and
the same document.

 

     

    

    

 

This Agreement contains the entire agreement between the parties hereto
with respect to the subject matter hereof.

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective
Date,

 

 

CLIENT

 

Zomedica Pharmaceuticals Corp.

 

 

/s/ Shameze Rampertab

Shameze Rampertab

Interim CEO and Director

 

 

 

CONSULTANT

 

/s/ Johnny D. Powers

 

Johnny D. Powerssrpt-ex44_474.htm

Exhibit 4.4

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934

The following description sets forth certain material terms and provisions of the common stock, par value $0.0001 per share, of Sarepta Therapeutics, Inc. (the “Company”, “us”, “we”, or “our”).  

For the complete terms of our common stock, please refer to our articles of incorporation and bylaws as amended and restated, each of which is an exhibit to the Annual Report on Form 10-K to which this description is an exhibit and to the applicable provisions of the Delaware General Corporation Law. 

COMMON STOCK 

Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a majority of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that is outstanding at the time of the dividend. In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution to stockholders after payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. All shares of common stock will, when issued, be duly authorized, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to the rights of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.  

Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law 

Certain provisions of Delaware law, our certificate of incorporation and our bylaws could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, encourage persons seeking to acquire control of us to first negotiate with our board of directors and the holders of our capital stock. 

Delaware Law 

We are subject to Section 203 of the Delaware General Corporation Law. This statute regulating corporate takeovers prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for three years following the date that the stockholder became an interested stockholder, unless: 

	
 
	
•
	
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; 

	
 
	
•
	
upon consummation of the transaction that resulted in the interested stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers, and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or 

	
 
	
•
	
on or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder. 

Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is any person who, together with such person’s affiliates and associates (i) owns 15% or more of a corporation’s voting securities or (ii) is an affiliate or associate of a corporation and was the owner of 15% or more of the corporation’s voting securities at any time within the three year period immediately preceding a business combination of the corporation governed by Section 203. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that Section 203 may discourage takeover attempts that might result in a premium over the market price for the shares of common stock held by our stockholders. 

Exhibit 4.4

Staggered board of directors 

Our certificate of incorporation and our bylaws divide our board of directors into two classes with staggered two-year terms, when the board is comprised of more than six members. Eight individuals currently serve on our board of directors, which is divided into two classes. At each annual meeting of stockholders, a class of directors is to be elected for a two-year term to succeed the directors of the same class whose terms are then expiring. As a result, a portion of our board of directors will be elected each year. Our bylaws authorize our board of directors to fix the number of directors from time to time by a resolution of the majority of our board of directors, provided the board shall consist of a minimum of one and a maximum of eight members. The division of our board of directors into two classes with staggered two-year terms may delay or prevent a change of our management or a change in control. Between stockholder meetings, directors may be removed by a vote of a majority of the voting power of all outstanding shares of voting stock only for cause. Under our certificate of incorporation and bylaws, any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office unless our board of directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders. These provisions may prevent a stockholder from removing incumbent directors and simultaneously gaining control of the board of directors by filling the resulting vacancies with its own nominees. The classification of our board of directors and the limitations on the ability of our stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company. 

Stockholder action; special meeting of stockholders; advance notice requirements for stockholder proposals and director nominations 

Our certificate of incorporation and our bylaws provide that any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of stockholders may only be taken if it is properly brought before such meeting and may not be taken by written action in lieu of a meeting. Our certificate of incorporation and our bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called by our president or our board of directors, or by our president at the request of holders of not less than one-tenth of all outstanding shares of capital stock. In addition, our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of the meeting or brought before the meeting by or at the direction of our board of directors, or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder’s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. These provisions also could discourage a third party from making a tender offer for our common stock, because even if it acquired a majority of our outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent. 

Super-majority voting 

The Delaware General Corporation Law provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation’s certificate of incorporation or bylaws, unless a corporation’s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our bylaws may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of our capital stock entitled to vote at an election of directors. In addition, the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of voting stock, voting together as a single class, is required to alter, amend or repeal certain provisions of our certificate of incorporation.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]